<DOC>
	<DOCNO>NCT00269204</DOCNO>
	<brief_summary>A 28-week clinical trial patient primary hypercholesterolemia mixed hyperlipidemia study effect MK0524A lipid tolerability . There 9 schedule clinic visit , 3 treatment group . A patient randomly assign 1 3 treatment group .</brief_summary>
	<brief_title>Lipid Efficacy/Tolerability Study ( 0524A-020 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type V</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patients 18 85 year age Primary Hypercholesterolemia Mixed Hyperlipidemia LDLC 100 mg/dL high risk patient ( patient Coronary Artery Disease ( CHD ) . Have medical condition consider CHD equivalent ) . LDLC 130 mg/dL patient multiple risk factor . LDLC 130 190 mg/dL patient low risk Triglycerides &lt; /= 350 mg/dL . A condition , opinion investigator , might pose risk patient interfere participate study , patient &lt; 20 % compliance , patient chronic medical condition , patient unstable dos medication . Pregnant lactate woman , woman intend become pregnant exclude . Patient diabetes mellitus poorly control , newly diagnose , recently experience repeat hypoglycemia unstable glycemic control , take new recently adjust antidiabetic pharmacotherapy ( exception +/ 10 unit insulin ) . Patients follow condition : chronic heart failure , uncontrolled/unstable cardiac arrhythmia , unstable hypertension , active chronic hepatobiliary hepatic disease , HIV positive , gout ( within 1 year ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>